Julia Feiser
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Julia Feiser has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Amalia Sophianidis
Department of Biosciences and Medical Biology, University of Salzburg, Salzburg, Austria
1 shared publication Andrew Hutton
Takeda Pharmaceuticals, Oncology Drug Discovery Unit, Cambridge, MA, USA
1 shared publication- Anshu Sharma
Department of Immunology, University of Toronto, Toronto, Ontario, Canada
1 shared publication - Christina Guttmann-Gruber
EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University, Salzburg, Austria
1 shared publication - Giorgia Nasi
Department of Biosciences and Medical Biology, University of Salzburg, Salzburg, Austria
1 shared publication - Iris Karina Gratz
Department of Biosciences and Medical Biology, University of Salzburg, Salzburg, Austria
1 shared publication
Latest Publications
- Open Access
- 26 June 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (26) , eaec7215
Harnessing skin-resident γδ T cells for immunotherapy in cutaneous squamous cell carcinoma
Gamma delta (γδ) T cells are critical for tissue immune surveillance and their presence in tumors correlates with a favorable prognosis, highlighting their therapeutic potential. Although γδ T cells are abundant in the skin, their therapeutic value in skin cancer has remained largely unexplored due to challenges in isolating sufficient numbers of γδ T cells from human tissues and a lack of suitable preclinical models for skin cancer. Here, we are using innovative methods to expand human cutaneous γδ T cells ex vivo, enabling us to investigate their therapeutic potential in a human cutaneous squamous cell carcinoma (cSCC) mouse model. In this model, γδ T cells were specifically recruited to and maintained in the cSCC xenograft. These tumor-infiltrating cells exhibited an activated, cytotoxic phenotype and demonstrated effective antitumor activity in vivo. Collectively, our findings provide preclinical evidence supporting human skin–resident γδ T cells as a promising immunotherapeutic approach for treating skin cancers such as cSCC.
- 26 June 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (26) , eaec7215
Open AccessHarnessing skin-resident γδ T cells for immunotherapy in cutaneous squamous cell carcinoma
Gamma delta (γδ) T cells are critical for tissue immune surveillance and their presence in tumors correlates with a favorable prognosis, highlighting their therapeutic potential. Although γδ T cells are abundant in the skin, their therapeutic value in skin cancer has remained largely unexplored due to challenges in isolating sufficient numbers of γδ T cells from human tissues and a lack of suitable preclinical models for skin cancer. Here, we are using innovative methods to expand human cutaneous γδ T cells ex vivo, enabling us to investigate their therapeutic potential in a human cutaneous squamous cell carcinoma (cSCC) mouse model. In this model, γδ T cells were specifically recruited to and maintained in the cSCC xenograft. These tumor-infiltrating cells exhibited an activated, cytotoxic phenotype and demonstrated effective antitumor activity in vivo. Collectively, our findings provide preclinical evidence supporting human skin–resident γδ T cells as a promising immunotherapeutic approach for treating skin cancers such as cSCC.